Cellectis announced a net loss of $101.1 million for Q3 2026, driven by a strategic transformation to focus on in vivo gene editing. The company reported promising preclinical results for its .HEAL-101 and .HEAL-201 gene editing programs targeting severe hypertriglyceridemia and hypercholesterolemia, with clinical trials planned in China starting in 2027 and 2028 respectively. Cash reserves stand at $149 million, supporting operations into H2 2028 despite reduced revenues and increased R&D expenses due to restructuring and program discontinuations. The company continues partnerships with AstraZeneca and Servier while realigning its workforce and operational model.
Cellectis' Q3 2026 financial update comes as a backdrop to the health sector's performance on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 06:01 WIB: out of 150 priced US health-sector stocks, 26 rose and 122 fell today. Notable movers include ARWR at USD 46.02 with a 1-day change of -6.77%, RXRX at USD 3.35 with balanced Pluang order activity of 50% Sell / 50% Buy, and MRNA at USD 232.70 with a 1-day change of -6.43% and a typical hold time on Pluang of 58 days.
Atlas Energy Corp. completed its first royalty acquisition for $15 million on producing oil and gas assets in Southwest Alberta, funded by cash. The company began generating royalty revenue immediately, earning $141,000 in just seven days post-acquis...
AELO Swiss Academy has transformed into an international airline pilot training organization with bases in Locarno, Lugano, and Cuneo, reflecting over 40 years of aviation heritage. The academy reported a 186% increase in operations in September 2026...
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
